High Hydrostatic Pressure Processing of Human Milk Increases Apelin and GLP-1 Contents to Modulate Gut Contraction and Glucose Metabolism in Mice Compared to Holder Pasteurization.


Journal

Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595

Informations de publication

Date de publication:
05 Jan 2022
Historique:
received: 21 11 2021
revised: 29 12 2021
accepted: 02 01 2022
entrez: 11 1 2022
pubmed: 12 1 2022
medline: 29 1 2022
Statut: epublish

Résumé

High hydrostatic pressure (HHP) processing is a non-thermal method proposed as an alternative to Holder pasteurization (HoP) for the sterilization of human breast milk (BM). HHP preserves numerous milk bioactive factors that are degraded by HoP, but no data are available for milk apelin and glucagon-like peptide 1 (GLP-1), two hormones implicated in the control of glucose metabolism directly and via the gut-brain axis. This study aims to determine the effects of HoP and HHP processing on apelin and GLP-1 concentrations in BM and to test the effect of oral treatments with HoP- and HHP-BM on intestinal contractions and glucose metabolism in adult mice. Mice were treated by daily oral gavages with HoP- or HHP-BM during one week before intestinal contractions, and glucose tolerance was assessed. mRNA expression of enteric neuronal enzymes known to control intestinal contraction was measured. HoP-BM displayed a reduced concentration of apelin and GLP-1, whereas HHP processing preserved these hormones close to their initial levels in raw milk. Chronic HHP-BM administration to mice increased ileal mRNA nNos expression level leading to a decrease in gut contraction associated with improved glucose tolerance. In comparison to HoP, HPP processing of BM preserves both apelin and GLP-1 and improves glucose tolerance by acting on gut contractions. This study reinforces previous findings demonstrating that HHP processing provides BM with a higher biological value than BM treated by HoP.

Sections du résumé

BACKGROUND BACKGROUND
High hydrostatic pressure (HHP) processing is a non-thermal method proposed as an alternative to Holder pasteurization (HoP) for the sterilization of human breast milk (BM). HHP preserves numerous milk bioactive factors that are degraded by HoP, but no data are available for milk apelin and glucagon-like peptide 1 (GLP-1), two hormones implicated in the control of glucose metabolism directly and via the gut-brain axis. This study aims to determine the effects of HoP and HHP processing on apelin and GLP-1 concentrations in BM and to test the effect of oral treatments with HoP- and HHP-BM on intestinal contractions and glucose metabolism in adult mice.
METHODS METHODS
Mice were treated by daily oral gavages with HoP- or HHP-BM during one week before intestinal contractions, and glucose tolerance was assessed. mRNA expression of enteric neuronal enzymes known to control intestinal contraction was measured.
RESULTS RESULTS
HoP-BM displayed a reduced concentration of apelin and GLP-1, whereas HHP processing preserved these hormones close to their initial levels in raw milk. Chronic HHP-BM administration to mice increased ileal mRNA nNos expression level leading to a decrease in gut contraction associated with improved glucose tolerance.
CONCLUSION CONCLUSIONS
In comparison to HoP, HPP processing of BM preserves both apelin and GLP-1 and improves glucose tolerance by acting on gut contractions. This study reinforces previous findings demonstrating that HHP processing provides BM with a higher biological value than BM treated by HoP.

Identifiants

pubmed: 35011094
pii: nu14010219
doi: 10.3390/nu14010219
pmc: PMC8747192
pii:
doi:

Substances chimiques

APLN protein, human 0
Apelin 0
Glucagon-Like Peptide 1 89750-14-1
Glucose IY9XDZ35W2

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Agence Nationale de la Recherche
ID : HHP-humanmilk

Références

Cell Metab. 2021 Jul 6;33(7):1466-1482.e7
pubmed: 34043943
Cell Metab. 2017 May 2;25(5):1075-1090.e5
pubmed: 28467926
Obesity (Silver Spring). 2013 Jul;21(7):1451-8
pubmed: 23408760
Diabetes. 2001 Aug;50(8):1720-8
pubmed: 11473030
J Clin Invest. 2005 Dec;115(12):3554-63
pubmed: 16322793
Diabetes. 2008 Oct;57(10):2603-12
pubmed: 18519802
Neurogastroenterol Motil. 2010 Jun;22(6):664-e203
pubmed: 20158614
Gut. 2021 Jun;70(6):1078-1087
pubmed: 33020209
Front Public Health. 2018 Nov 06;6:306
pubmed: 30460221
Mol Metab. 2018 Apr;10:100-108
pubmed: 29428595
Physiol Rev. 2007 Oct;87(4):1409-39
pubmed: 17928588
Clin Perinatol. 2021 Jun;48(2):229-250
pubmed: 34030811
J Mammary Gland Biol Neoplasia. 2017 Sep;22(3):171-191
pubmed: 28653126
Neurogastroenterol Motil. 2019 Feb;31(2):e13482
pubmed: 30303298
Am J Physiol. 1995 Dec;269(6 Pt 1):G945-52
pubmed: 8572226
Acta Diabetol. 2021 Jul;58(7):881-897
pubmed: 33723651
Foods. 2021 Jun 09;10(6):
pubmed: 34207614
Clin Perinatol. 2017 Mar;44(1):95-119
pubmed: 28159212
Gut. 2017 Feb;66(2):258-269
pubmed: 26565000
Front Pediatr. 2018 Nov 16;6:323
pubmed: 30519550
J Nutr. 2007 Nov;137(11 Suppl):2534S-2538S
pubmed: 17951498
Front Immunol. 2018 Sep 27;9:2222
pubmed: 30319659
Neuroendocrinology. 2020;110(1-2):139-146
pubmed: 31280267

Auteurs

Eve Wemelle (E)

INSERM U1220, Institut de Recherche en Santé Digestive (IRSD), Université Paul Sabatier, Toulouse III, CHU Purpan, Place du Docteur Baylac, CS 60039, CEDEX 3, 31024 Toulouse, France.
European Associated Laboratory (EAL) «NeuroMicrobiota», International Research Projects (IRP) INSERM, 1000 Brussels, Belgium.
European Associated Laboratory (EAL) «NeuroMicrobiota», International Research Projects (IRP) INSERM, 31024 Toulouse, France.

Lucie Marousez (L)

Univ. Lille, Inserm, CHU Lille, U1286-INFINITE-Institute for Translational Research in Inflammation, F-59000 Lille, France.

Marie de Lamballerie (M)

UMR CNRS 6144 GEPEA, ONIRIS, CS 82225, 44322 Nantes, France.

Claude Knauf (C)

INSERM U1220, Institut de Recherche en Santé Digestive (IRSD), Université Paul Sabatier, Toulouse III, CHU Purpan, Place du Docteur Baylac, CS 60039, CEDEX 3, 31024 Toulouse, France.
European Associated Laboratory (EAL) «NeuroMicrobiota», International Research Projects (IRP) INSERM, 1000 Brussels, Belgium.
European Associated Laboratory (EAL) «NeuroMicrobiota», International Research Projects (IRP) INSERM, 31024 Toulouse, France.

Jean Lesage (J)

Univ. Lille, Inserm, CHU Lille, U1286-INFINITE-Institute for Translational Research in Inflammation, F-59000 Lille, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH